(R)-2-thioacetyl-4-methylpentanoic acid | 122999-38-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (R)-2-thioacetyl-4-methylpentanoic acid
• 英文别名: (2R)-2-acetylsulfanyl-4-methylpentanoic acid
• CAS: 122999-38-6
• 化学式: C₈H₁₄O₃S
• 分子量: 190.263
• InChiKey: JBFQRXOFTJJNEV-SSDOTTSWSA-N

物化性质

• 沸点：
  91-94 °C(Press: 0.4 Torr)
• 密度：
  1.138±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  79.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-2-thioacetyl-4-methylpentanoic acid 在 氨 、 1,4-二巯基-2,3-丁二醇 作用下， 以 水 为溶剂， 反应 5.0h， 生成 (R)-2-mercapto-4-methylpentanoic acid
  参考文献：
  名称：

  设计和合成发色的硫代peptolide底物作为MetAPs活性位点探针。

  摘要：

  设计并合成了二十一种生色硫代peptolide底物作为活性位点探针，并用突变型残基的每个S1位点和野生型MetAP1s的酶进行了分析。初步的酶促实验表明，大肠杆菌或人MetAP1上的半胱氨酸70或202在蛋氨酸水解中起着至关重要的作用。

  DOI：

  10.1016/j.bmc.2004.03.044
• 作为产物：
  描述：

  D-亮氨酸 在 氢氧化钾 、 sodium nitrate 、 氢溴酸 作用下， 以 乙醇 为溶剂， 反应 17.33h， 生成 (R)-2-thioacetyl-4-methylpentanoic acid
  参考文献：
  名称：

  Phosphoramidate peptide inhibitors of human skin fibroblast collagenase

  摘要：

  An extensive series of N-(monoethylphosphoryl)peptides was synthesized and their inhibition of purified human skin fibroblast collagenase examined. At the cleavage site S1 all reported compounds have the (EtO)(OK)P(O) group and the peptide side chain extended toward the C-terminal end (up to P5') of the substrate sequence. These phosphoramidates with a tetrahedrally hybridized phosphorus atom are thought to be transition state analogue inhibitors. They exhibited fair inhibitory potency against this vertebrate collagenase having Ki values in the micromolar range. The most potent of these, (EtO)(OK)P(O)-Ile-TrpNHCH3 (68), inhibits with a Ki value of 1.5 microM and is nearly 100 times stronger than (EtO)(OK)P(O)-Ile-Ala-GlyOK (51) (Ki of 140 microM), which has the sequence matching that of the alpha 1 (I) chain of collagen in P1', P2', P3' after the cleavage site. Several compounds were prepared in an attempt to identify the nature of the S2', S3', and S4' binding sites. Alanine at the P2' position was replaced by leucine, phenylalanine, tryptophan, or tyrosine derivatives, resulting in Ki values in a significantly lower range, 1.0-40 microM, compared to 51. No upper size limitation or specificity has been found at this position, yet similar replacements at the P3' position, which is occupied naturally by a glycine residue, gave weaker inhibitors: (EtO)(OK)P(O)-Ile-Tyr(OBzl)-PheOK (57) had a Ki of 120 microM. Hexapeptide derivatives had weaker activities in the 270 microM-2 mM range. All inhibitors were evaluated by using the synthetic thio peptolide spectrophotometric assay.

  DOI：

  10.1021/jm00163a044

文献信息

• Dual-acting antihypertensive agents
  申请人：Allegretti Paul

  公开号：US20080269305A1

  公开（公告）日：2008-10-30

  The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R 5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  该发明涉及具有以下公式的化合物：其中：Ar、r、Y、Z、Q、W、X和R5-7如规范中定义，并且其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和神经肽酶抑制活性。该发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• Dual-acting Imidazole antihypertensive agents
  申请人：Allegretti Paul

  公开号：US20090023228A1

  公开（公告）日：2009-01-22

  The invention is directed to compounds having the formula: wherein: Ar, r, R 2-3 , X, and R 5.7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  本发明涉及具有以下结构式的化合物：其中：Ar、r、R2-3、X和R5.7如规范中所定义，并且其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和神经肽酶抑制活性。本发明还涉及包含这些化合物的制药组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• DUAL-ACTING ANTIHYPERTENSIVE AGENTS
  申请人：Allegretti Paul

  公开号：US20110281925A1

  公开（公告）日：2011-11-17

  The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R 5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  该发明涉及具有以下式子的化合物：其中：Ar、r、Y、Z、Q、W、X和R5-7如规范中所定义，并且其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和酶解酶抑制活性。该发明还涉及包含这些化合物的制药组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS
  申请人：ALLEGRETTI Paul

  公开号：US20110092551A1

  公开（公告）日：2011-04-21

  The invention is directed to compounds having the formula: wherein: Ar, r, R 2-3 , X, and R 5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  本发明涉及具有下式的化合物：其中：Ar，r，R2-3，X和R5-7如说明书所定义，以及其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和酶解酶抑制活性。本发明还涉及包含这些化合物的制药组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• KORTYLEWICZ, ZBIGNIEW P.;GALARDY, RICHARD E., J. MED. CHEM., 33,(1990) N, C. 263-273
  作者：KORTYLEWICZ, ZBIGNIEW P.、GALARDY, RICHARD E.

  DOI：——

  日期：——